Solid Tumor, Adult
Conditions
Brief summary
Fifteen cohorts will be opened. Each cohort will explore one analysis method and/or tumoral type. Up to 50 patient can be included into each cohort.
Interventions
PROCEDUREBlood sampling
Sponsors
Institut Curie
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years old or more * Performance status from 0 to 4 * Patient treated followed for histologically confirmed solid tumor type of any of these localization : breast, prostate, uterus, ovary, colon, lung, head and neck, melanoma. * Informed consent form signed.
Exclusion criteria
* Patient with history of other invasive cancer within 5 years. * Patient treated for any non-invasive cancer * Patient individually deprived of liberty or placed under the authority of a tutor * Geographical condition potentially preventing compliance with the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CTC, CEC or ctDNA incidence | 3 years | number of CTC or CEC in 7.5ml of blood |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CTC and CEC molecular characterization | 3 years | This outcome is self-explanatory. |
| Circulating tumor DNA (ctDNA) detection and quantification | 3 years | plasma mutation detection (number of copy) |
Countries
France
Outcome results
None listed